Arrowhead Research
ARWR • NASDAQ
Arrowhead Research is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Christopher R. Anzalone, with a market cap of $8.1B.
CEOChristopher R. Anzalone
Next Earnings
Upcoming earnings announcement for Arrowhead Research
Date
Monday, May 11, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q2 2026
EPS Estimate
-$1.02
Revenue Estimate
$79.7M
Earnings History
Past 12 earnings reports for Arrowhead Research
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 5, 2026 | Q1 2026 | $0.22Est: $0.02 | +1000.0% | $264.0MEst: $256.6M | +2.9% |  10-Q |
| Nov 25, 2025 | Q4 2025 | -$0.18Est: -$0.05 | -260.0% | $256.5MEst: $175.5M | +46.1% | 10-K |
| Aug 7, 2025 | Q3 2025 | -$1.26Est: -$1.04 | -21.2% | $27.8MEst: $33.8M | -17.8% | 10-Q |
| May 12, 2025 | Q2 2025 | $2.75Est: -$0.46 | +697.8% | $542.7MEst: $116.3M | +366.8% | 10-Q |
| Feb 10, 2025 | Q1 2025 | -$1.39Est: -$0.72 | -93.1% | $2.5MEst: $19.1M | -86.9% | 10-Q |
| Nov 26, 2024 | Q4 2024 | -$1.37Est: -$0.92 | -48.9% | -Est: $58.9M | -100.0% | 10-K |
| Aug 8, 2024 | Q3 2024 | -$1.38Est: -$0.55 | -150.9% | -Est: $52.6M | -100.0% | 10-Q |
| May 9, 2024 | Q2 2024 | -$1.02Est: -$0.16 | -537.5% | - | — | 10-Q |
| Feb 6, 2024 | Q1 2024 | -$1.24Est: -$0.82 | -51.2% | $3.6MEst: $29.5M | -88.0% | 10-Q |
| Nov 29, 2023 | Q4 2023 | -$1.02Est: -$0.60 | -70.0% | $16.1MEst: $50.7M | -68.3% | — |
| Aug 7, 2023 | Q3 2023 | -$0.96Est: -$0.58 | -65.5% | $15.8MEst: $48.2M | -67.2% | — |
| May 2, 2023 | Q2 2023 | $0.45Est: -$0.64 | +170.3% | $146.3MEst: $45.5M | +221.6% | — |